All In Biotech

Drug Trial Radar · NCT02900664

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Last checked: Nov 20, 2026Latest source record: Mar 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

283

Actual

Start

Aug 23, 2016

Primary completion

Mar 17, 2021

Study completion Mar 17, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Conditions

  • Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Interventions

  • PDR001Biological

    Powder for solution for infusion

  • ACZ885Biological

    Solution for injection

  • CJM112Biological

    Solution for infusion

  • TMT212Drug

    Tablets

  • EGF816Drug

    Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: Throughout the study at every visit, an average of 1 year
  2. Changes between baseline and post-baseline laboratory parameters and vital signs.Time frame: Baseline and throughout the study at every visit, an average of 1 year
  3. Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)Time frame: During the first two cycles; Cycle = 28 days
  4. Frequency of dose interruptionsTime frame: Throughout the study at every visit, an average of 1 year
  5. Dose intensitiesTime frame: Throughout the study at every visit, an average of 1 year
  6. Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: Throughout the study at every visit, an average of 1 year
  7. Frequency of dose reductionsTime frame: Throughout the study at every visit, an average of 1 year

Locations

23 sites in 9 countries. Site status is shown where the registry gives one.

  • Sidney Kimmel Comprehensive Cancer Center SC-3

    Baltimore, Maryland

  • Dana Farber Cancer Center

    Boston, Massachusetts

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Novartis Investigative Site

    Tainan, Taiwan

  • Novartis Investigative Site

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.